BioCentury | Oct 8, 2019

Novel targets induce cardiomyocyte regeneration

DISEASE CATEGORY: Cardiovascular INDICATION: Myocardial infarction (MI) Gene therapies delivering CCL24 or IGF2BP3 could restore cardiac function following MI. RNA-seq analysis identified 874 genes including CCL24 and IGF2BP3 that were upregulated in mouse heart tissue...
BioCentury | Oct 3, 2019
Targets & Mechanisms

Stimulating heart regeneration following injury

A multi-omic study of regenerating neonatal hearts has uncovered novel therapeutic targets for cardiac injury post myocardial infarction. Study leader Eric Olson said the findings serve as a resource for understanding the DNA sequences and...
BioCentury | Aug 21, 2019
Financial News

Oncorus raises $79.5M series B with eye on global development

Nearly half a dozen Korean investment groups joined Oncorus' $79.5 million series B round as part of the company's long-range plan to take its oncolytic virus technology global. Cowen Healthcare Investments and Perceptive Advisors led...
BioCentury | Aug 3, 2018
Targets & Mechanisms

Oxitope’s oxidation play

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The...
BioCentury | Jul 12, 2018
Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
BioCentury | May 15, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis In vitro and mouse studies identified a chemokine-targeting single-chain variable fragment (scFv)-based fusion protein that could help treat arthritis. Screening of a scFv library for binding to various human and mouse chemokines, engineering...
BioCentury | Dec 8, 2017
Financial News

OrbiMed , Thiel lead ChemomAb's $10M series B

Antibody company ChemomAb Ltd. (Tel Aviv, Israel) raised $10 million in a series B round on Dec. 4 led by OrbiMed Israel and Peter Thiel. SBI Japan-Israel Innovation Fund and Milestone Venture also participated. The...
BioCentury | Dec 4, 2017
Financial News

OrbiMed, Thiel lead ChemomAb's $10M series B

Antibody company ChemomAb Ltd. (Tel Aviv, Israel) raised $10 million in a series B round led by OrbiMed Israel and Peter Thiel. SBI Japan-Israel Innovation Fund and Milestone Venture also participated. The company previously raised...
BioCentury | Nov 28, 2017
Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest inhibiting CCR5 or its interactions with CCL3, CCL4 and RANTES could help treat melanoma. In patient tissue samples, the number of CCR5-positive myeloid-derived suppressor cells (MDSC) and...
BioCentury | May 8, 2017
Distillery Therapeutics

Dermatology

INDICATION: Wounds Patient sample and mouse studies suggest a topical hydrogel that scavenges MCP-1 , CCL3 , CCL4 and other inflammatory factors could help treat chronic wounds. The hydrogel consisted of star-shaped PEG (starPEG) and glycosaminoglycans containing...
Items per page:
1 - 10 of 50